Patent · US Active

Alteration of Fc-fusion protein serum half-lives by mutagenesis

US7732570B2 · kind B2 · utility

7Cited by
17References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 14, 2007
Grant dateJun 8, 2010
Priority date
Expiry dateMay 27, 2028

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/30
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.